Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 76Neoplasms 16Prostatic Neoplasms, Castration-Resistant 14Neoplasm Metastasis 9Breast Neoplasms 9Metastatic Castration Resistant Prostate Cancer 8Prostate Cancer Metastatic 5Metastatic Castration-Resistant Prostate Cancer 5Colorectal Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Carcinoma, Non-Small-Cell Lung 4Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Metastatic Castration-resistant Prostate Cancer 3Melanoma 3Bulbo-Spinal Atrophy, X-Linked 3mCRPC 2Recurrence 2Pancreatic Neoplasms 2Non-metastatic Castration-resistant Prostate Cancer 2Metastatic Hormone-sensitive Prostate Cancer 2Metastatic Hormone Sensitive Prostate Cancer 2Metastatic Castrate-Resistant Prostate Cancer 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Bites and Stings 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Solid Tumours 1Seizures 1

Interventions

pembrolizumab 3enzalutamide 2blinatumomab 2abiraterone 2Immune Checkpoint Inhibitors 2Cytochrome P-450 Enzyme System 2AMG 757 2durvalumab 1dostarlimab 1cemiplimab 1atezolizumab 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Hydroxyurea 1Etoposide 1Etanercept 1Carboplatin 1Androgen Receptor Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Bites and Stings × enzalutamide × Clear all
NCT04221542 2026-05-29

Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

Amgen

Phase 1 Recruiting
479 enrolled
Genitourinary

Bites and Stings, Prostatic Neoplasms

NCT04631601 2025-10-07

Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

Amgen

Phase 1/2 Terminated
65 enrolled

Bites and Stings

Data powered by HemOnc (CC BY 4.0) Colophon âš¡